Arenit H1 2026 slides: sales surge 54%, leverage turns negative

ARENIT Industries reported H1 2026 net sales of €45.6M (+54% YoY) and EBITA of €7.7M (+67% YoY), with EBITA margin up to 17% from 16%. The balance sheet improved sharply as net debt swung to net cash of -€7.7M (from +€23.7M at YE2025) supported by €54.6M cash and €8.3M operating cash flow in H1, while management expects 2–4 more acquisitions in 2H26 (EV/EBITDA purchase discipline unchanged). Despite the strong fundamentals, shares fell 3.88% to $99 vs $103, likely reflecting Q2 seasonal margin softness and macro/DACH headwinds.

Analysis

The investable signal here is balance-sheet optionality, not the reported growth itself. A net-cash industrial roll-up with a disciplined acquisition hurdle can compound faster than the local GDP tape if management can keep buying private assets below public-market multiples; that is the real reason the stock deserves a premium when deal flow is healthy. The counterpoint is that this model is highly sensitive to the price paid for the next 2-4 acquisitions: if private sellers reprice lower than public comps but integration costs rise, the equity story can flatten quickly even with solid reported growth.

Second-order, this is a favorable setup for smaller DACH niche suppliers that can be sold into a consolidator with dry powder, while more levered regional peers lose relative bargaining power. The main risk is timing: margin noise from labor normalization and Q4 seasonality can suppress the next print before any M&A accretion shows up, so the market may continue to discount the stock for several weeks despite good fundamentals. If PMI weakens further or cost pass-through stalls, the thesis shifts from “compounder” to “cyclical with acquisition risk.”

Contrarian view: the market may be underestimating how scarce net-cash M&A platforms are in a soft industrial tape, and that scarcity can support valuation even when headline margins wobble. For TGT specifically, there is no meaningful read-through; the impact score is effectively zero, so this is not a retail or U.S. consumer trade. The actionable edge is to wait for evidence that the next deal closes at the stated mid-single-digit multiple and that order intake remains stable; otherwise, this is a watch item rather than a buy-the-dip setup.

Key Decisions for Investors

• No position change in TGT on this news; the estimated read-through is zero and there is no direct mechanism into U.S. retail margins or traffic.
• Watch ARENIT-like European small-cap industrial compounders for a pullback entry only after the next acquisition is announced at <=7x EV/EBITDA and organic growth stays >10%; if not, stay flat.
• If DACH macro weakens again over the next 1-3 months, fade levered regional industrials and prefer cash-rich consolidators; use a relative-value basket rather than a directional macro bet.
• Set a trigger to reassess if reported EBITDA margin falls back below 15% or if management pushes beyond the stated acquisition valuation discipline; that would falsify the compounder premium thesis.